CBIO (Crescent Biopharma) OCF Margin %: -860.15% (As of Mar. 2026)


CBIO Crescent Biopharma Inc CBIO
10 GF Score
Price $18.56
! 2 Warning Signs
View Full Analysis

What is Crescent Biopharma OCF Margin %?

Crescent Biopharma CBIO +9.24% 10 OCF Margin % is -860.15% as of Mar. 2026. GuruFocus rates CBIO with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 959 Biotechnology companies, Crescent Biopharma ranks worse than 75.18% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Crescent Biopharma's Cash Flow from Operations for the three months ended in Mar. 2026 was $-8.94 Mil. Crescent Biopharma's Revenue for the three months ended in Mar. 2026 was $1.04 Mil. Therefore, Crescent Biopharma's OCF Margin % for the quarter that ended in Mar. 2026 was -860.15%.

As of today, Crescent Biopharma's current OCF Yield % is -13.60%.

The historical rank and industry rank for Crescent Biopharma's OCF Margin % or its related term are showing as below:

CBIO' s OCF Margin % Range Over the Past 10 Years
Min: -659.65   Med: -659.65   Max: -659.65
Current: -585.86

During the past 2 years, the highest OCF Margin % of Crescent Biopharma was -659.65%. The lowest was -659.65%. And the median was -659.65%.

CBIO's OCF Margin % is ranked worse than
75.18% of 959 companies
in the Biotechnology industry
Industry Median: -66.52 vs CBIO: -585.86

Crescent Biopharma OCF Margin % Related Terms

Crescent Biopharma OCF Margin % Historical Data

* Premium members only.

The historical data trend for Crescent Biopharma's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Crescent Biopharma OCF Margin % Chart

Crescent Biopharma Annual Data
Trend Dec24 Dec25
OCF Margin %
0.00 -659.65

Crescent Biopharma Quarterly Data
Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial 0.00 0.00 0.00 -246.59 -860.15

CBIO vs RIGL, GYRE, TRAX: OCF Margin % Comparison

For the Biotechnology subindustry, Crescent Biopharma's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Crescent Biopharma OCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Crescent Biopharma's OCF Margin % distribution charts can be found below:

* The bar in red indicates where Crescent Biopharma's OCF Margin % falls into.


CBIO
10GF Score
Crescent Biopharma Inc CBIO
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Crescent Biopharma OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Crescent Biopharma's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-71.532/10.844
=-659.65 %

Crescent Biopharma's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-8.937/1.039
=-860.15 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of -860.15% mean?
Crescent Biopharma (CBIO) has a OCF Margin % of -860.15% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Crescent Biopharma and its competitors. According to the industry distribution chart, Crescent Biopharma ranks #721 out of 959 companies in the Biotechnology industry, placing it in the top 75.2%.
Is Crescent Biopharma's OCF Margin % too high?
Crescent Biopharma's current OCF Margin % is -860.15%. Based on the distribution chart, Crescent Biopharma ranks #721 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Crescent Biopharma has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Crescent Biopharma's OCF Margin % compare to RIGL and GYRE?
According to the Biotechnology industry distribution chart, Crescent Biopharma ranks #721 out of 959 companies for OCF Margin %. This places Crescent Biopharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Crescent Biopharma and its competitors. Crescent Biopharma's current OCF Margin % is -860.15%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crescent Biopharma stock overvalued right now?
Crescent Biopharma (CBIO) has a current OCF Margin % of -860.15%. The current OCF Margin % is -860.15%. Crescent Biopharma's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Crescent Biopharma (CBIO), the current OCF Margin % is -860.15% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Crescent Biopharma Business Description

Other Exchanges C68:Germany
Address 300 Fifth Avenue, Waltham, MA, USA, 02451
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
10GF Score

Get the complete analysis for CBIO

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$18.56
Price